Literature DB >> 6369971

Insulin secretion and action in noninsulin-dependent diabetes mellitus. Is insulin resistance secondary to hypoinsulinemia?

G M Reaven, Y I Chen, A M Coulston, M S Greenfield, C Hollenbeck, C Lardinois, G Liu, H Schwartz.   

Abstract

The insulin-stimulated glucose metabolic clearance rate, assessed by the insulin clamp technique, was compared in 40 normal subjects and 40 age- and weight-matched patients with noninsulin-dependent diabetes mellitus. These studies were conducted at steady-state plasma insulin levels of approximately 100 microU/ml, and the mean (+/- standard error of the mean) glucose metabolic clearance rate of patients with noninsulin-dependent diabetes mellitus was 81 +/- 9 ml/m2 per minute, as compared with a value of 235 +/- 14 ml/m2 per minute for normal subjects. This difference was highly statistically significant (p less than 0.001) and documents the extreme resistance to insulin-stimulated glucose utilization seen in noninsulin-dependent diabetes mellitus. Patients with noninsulin-dependent diabetes mellitus were also shown to have a lower than normal plasma insulin response to an oral glucose challenge. In contrast, ambient plasma insulin concentrations of normal subjects and patients with noninsulin-dependent diabetes mellitus were found to be quite comparable when measured throughout the day in response to the ingestion of conventional mixed meals. Consequently, absolute hypoinsulinemia is not characteristic of patients with noninsulin-dependent diabetes mellitus under conditions of daily living. Finally, the ability of intensive insulin treatment to improve insulin resistance was studied after one and six weeks of therapy. These results indicated that successful control of hyperglycemia led to a significant improvement in insulin action as early as one week after the initiation of insulin therapy, with no further changes noted after prolonged insulin administration. The degree to which insulin action approached normal values was greater when studies were carried out at circulating insulin levels of approximately 2,000 microU/ml as compared with insulin levels of approximately 100 microU/ml, but in both instances insulin-treated diabetic patients remained insulin-resistant as compared with normal subjects. These results have corroborated the fact that abnormalities of both insulin action and secretion can be documented in patients with noninsulin-dependent diabetes mellitus. However, patients with noninsulin-dependent diabetes mellitus were not found to be absolutely hypoinsulinemic in their daily existence, and control of their hyperglycemia with exogenous insulin did not restore insulin-stimulated glucose utilization to normal. Consequently, these data are not consistent with the view that the insulin resistance in noninsulin-dependent diabetes mellitus is entirely a secondary consequence of the hypoinsulinemia presumed to be present in these patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6369971     DOI: 10.1016/0002-9343(83)90258-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Plasma insulin concentration is useful to guide glucose supplement in insulin overdose.

Authors:  Paul Lee; Jerry R Greenfield; Jacqueline R Center; Lesley V Campbell
Journal:  Intensive Care Med       Date:  2008-08-06       Impact factor: 17.440

2.  The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass.

Authors:  W J Pories; J F Caro; E G Flickinger; H D Meelheim; M S Swanson
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

3.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes.

Authors:  J F Caro; M K Sinha; S M Raju; O Ittoop; W J Pories; E G Flickinger; D Meelheim; G L Dohm
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

4.  Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity.

Authors:  J F Caro; O Ittoop; W J Pories; D Meelheim; E G Flickinger; F Thomas; M Jenquin; J F Silverman; P G Khazanie; M K Sinha
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

5.  alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population.

Authors:  Walter E Gall; Kirk Beebe; Kay A Lawton; Klaus-Peter Adam; Matthew W Mitchell; Pamela J Nakhle; John A Ryals; Michael V Milburn; Monica Nannipieri; Stefania Camastra; Andrea Natali; Ele Ferrannini
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

6.  Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.

Authors:  Robert A Rizza
Journal:  Diabetes       Date:  2010-08-12       Impact factor: 9.461

7.  Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first degree relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  A Handberg; A Vaag; J Vinten; H Beck-Nielsen
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

8.  Long-term effect of insulin on glucose transport and insulin binding in cultured adipocytes from normal and obese humans with and without non-insulin-dependent diabetes.

Authors:  M K Sinha; L G Taylor; W J Pories; E G Flickinger; D Meelheim; S Atkinson; N S Sehgal; J F Caro
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

9.  Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

Authors:  D Giugliano; A Quatraro; G Consoli; A Minei; A Ceriello; N De Rosa; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Subcellular distribution of GLUT 4 in the skeletal muscle of lean type 2 (non-insulin-dependent) diabetic patients in the basal state.

Authors:  B Vogt; C Mühlbacher; J Carrascosa; B Obermaier-Kusser; E Seffer; J Mushack; D Pongratz; H U Häring
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.